Investor confidence in a potential acquisition of Acadia Pharmaceuticals (NASDAQ: ACAD) seems to have waned, and …
Acadia's stock dropped hard yesterday on a report from CNN, but that doesn't mean it's time to buy.
especially with off-label usage and label expansion all very big parts of the ACAD stock story going forward. If Acadia struggles out the gate with Nuplazid, or encounters typical setbacks that one should expect from a first-time …
Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) traded down about 27% Monday to post a new 52-week low of $15.74 after closing Friday at $21.53. The stock’s 52 …
Facebook hasn't disclosed that some of its revenue may be tied to illegal trafficking in wildlife in regulatory filings that are supposed to outline various risks and other …
The big question is whether big pharma values ACAD stock the same way that Acadia Pharmaceuticals management does. I think that’s the big disconnect right now. Acadia Pharmaceuticals has a market capitalization over $5 billion, …
ACADIA Pharmaceuticals Inc. ACAD is scheduled to report second-quarter 2016 results on Aug 4 after the market closes. In the last reported quarter, ACADIA had posted a negative earnings surprise of -12.5%. Let’s see how things are …